Correction to: Use of Physiologically Based Pharmacokinetic (PBPK) Modeling for Predicting Drug-Food Interactions: an Industry Perspective

Arian Emami Riedmaier; Kevin DeMent; James Huckle; Phil Bransford; Cordula Stillhart; Richard Lloyd; Ravindra Alluri; Sumit Basu; Yuan Chen; Varsha Dhamankar; Stephanie Dodd; Priyanka Kulkarni; Andrés Olivares-Morales; Chi-Chi Peng; Xavier Pepin; Xiaojun Ren; Thuy Tran; Christophe Tistaert; Tycho Heimbach; Filippos Kesisoglou; Christian Wagner; Neil Parrott

doi:10.1208/s12248-020-00535-z

Correction to: Use of Physiologically Based Pharmacokinetic (PBPK) Modeling for Predicting Drug-Food Interactions: an Industry Perspective

AAPS J. 2020 Nov 26;23(1):6. doi: 10.1208/s12248-020-00535-z.

Authors

Arian Emami Riedmaier¹, Kevin DeMent², James Huckle³, Phil Bransford⁴, Cordula Stillhart⁵, Richard Lloyd⁶, Ravindra Alluri⁷, Sumit Basu⁸, Yuan Chen⁹, Varsha Dhamankar^{10

11}, Stephanie Dodd¹², Priyanka Kulkarni¹³, Andrés Olivares-Morales¹⁴, Chi-Chi Peng^{13

15}, Xavier Pepin¹⁶, Xiaojun Ren¹⁷, Thuy Tran¹⁸, Christophe Tistaert¹⁹, Tycho Heimbach²⁰, Filippos Kesisoglou²¹, Christian Wagner²², Neil Parrott¹⁴

Affiliations

¹ DMPK and Translational Modeling, AbbVie Inc., North Chicago, Illinois, USA. arian.emamiriedmaier@abbvie.com.
² Global DMPK, Takeda Pharmaceutical Co., Ltd., San Diego, California, USA.
³ Drug Product Technology, Amgen, Thousand Oaks, California, USA.
⁴ Modeling & Informatics, Vertex Pharmaceuticals, Boston, Massachusetts, USA.
⁵ Pharmaceutical R&D, Formulation & Process Sciences, F.Hoffmann-La Roche Ltd., Basel, Switzerland.
⁶ Computational & Modelling Sciences, Platform Technology Sci-ences, GlaxoSmithKline R&D, Ware, Hertfordshire, UK.
⁷ Clinical Pharmacology and Safety Sciences, R&D, AstraZeneca, Cambridge, UK.
⁸ Pharmacokinetic, Pharmacodynamic and Drug Metabolism-Quantitative Pharmacology and Pharmacometrics (PPDM-QP2),Merck & Co, Inc., West Point, Pennsylvania, USA.
⁹ Department of Drug Metabolism and Pharmacokinetics, Genentech, South San Francisco, California, USA.
¹⁰ Formulation Development, Vertex Pharmaceuticals, Boston, Massachusetts, USA.
¹¹ Formulation Development, Cyclerion Therapeu-tics Inc., Cambridge, Massachusetts, USA.
¹² Chemical & Pharmaceutical Profiling, Novartis Institutes for Biomedical Research, Cambridge, Massachusetts, USA.
¹³ Department of Pharmacokinetics and Drug Metabolism, AmgenInc, Cambridge, Massachusetts, USA.
¹⁴ Pharmaceutical Sciences, Roche Pharmaceutical Research andEarly Development, Roche Innovation Center, Basel, Switzerland.
¹⁵ Drug Metabolism and Pharmacokinetics, Theravance Biopharma, South San Francisco, California, USA.
¹⁶ New Modalities and Parenteral Development, PharmaceuticalTechnology & Development, Operations, AstraZeneca, Maccles-field, UK.
¹⁷ Modeling & Simulation, PK Sciences, Novartis Institutes of Biomedical Research, East Hanover, New Jersey, USA.
¹⁸ Computational & Modelling Sciences, Platform Technology Sci-ences, GlaxoSmithKline R&D, Collegeville, Pennsylvania, USA.
¹⁹ Pharmaceutical Sciences, Janssen Research & Development, Beerse, Belgium.
²⁰ PBPK & Biopharmaceutics, Novartis Institutes of Biomedical Research, Wayne, New Jersey, USA.
²¹ Pharmaceutical Sciences, Merck & Co., Inc., Kenilworth, New Jersey, USA.
²² Pharmaceutical Technologies, Chemical and Pharmaceutical De-velopment, Merck Healthcare KGaA, Darmstadt, Germany.

Abstract

An Erratum to this paper has been published: https://doi.org/10.1208/s12248-020-00535-z.

Publication types

Published Erratum